

SpectraCure's main owner subscribes in full for his share

SpectraCure's main owner and CEO Masoud Khayyami subscribes in full through his company Cardeon Futuring Finance his share in the company's warrants program TO3, corresponding to 1 653 382 warrants. Cardeon Futuring Finance's total holding in SpectraCure after the issue amounts to 2 480 073 shares.

Prior to the acquisition Masoud Khayyami, privately and with companies owned 13 227 059 shares, corresponding to 16.21% of capital and votes. Following the acquisition, Masoud Khayyami, privately and with companies owns 14 053 750 shares.

Subscription of shares supported by the warrants in the TO3 program, implies that every two (2) warrants entitles the holder to subscribe for one (1) new share in SpectraCure at the subscription price of SEK 6.50. The subscription period for SpectraCure's TO3 subscription program started Friday, November 1st and lasts until Friday, November 29th. If all warrants are fully exercised, the company cash position will increase by a total of approximately MSEK 37.1 after deduction of related issue costs.

For further information, contact:

SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46(0) 70 815 21 90.

Certified Adviser is G&WFondkommission, e-mail: ca@qwkapital.se, phone: +46-(8)-503 000 50.

SpectraCure in short

SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer tumours in the head and neck region